Antibody, Immunoglobulin, Or Fragment Thereof Fused Via Peptide Linkage To Nonimmunoglobulin Protein, Polypeptide, Or Fragment Thereof (i.e., Antibody Or Immunoglobulin Fusion Protein Or Polypeptide) Patents (Class 424/134.1)
  • Patent number: 10800841
    Abstract: Methods of treating individuals with autoimmune conditions characterized by elevated IL-6 levels comprising the administration of anti-IL-6 antibodies or antibody fragments are provided.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: October 13, 2020
    Assignee: VITAERIS, INC.
    Inventors: Leon Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, Ethan W. Ojala, John Latham, Brian R. Kovacevich, Jeffrey T. L. Smith
  • Patent number: 10799558
    Abstract: This invention relates to the use of a CD24 protein for treating leptin-deficient conditions, such as lipodystrophy, by increasing the level of circulating leptin.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: October 13, 2020
    Assignee: ONCOIMMUNE, INC.
    Inventors: Yang Liu, Pan Zheng, Martin Devenport
  • Patent number: 10800840
    Abstract: The present invention provides compositions and methods for generating a genetically modified T cells comprising a chimeric antigen receptor (CAR) having an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain, wherein the T cell exhibits prolonged exponential expansion in culture that is ligand independent and independent of the addition of exogenous cytokines or feeder cells.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: October 13, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Matthew J. Frigault, Yangbing Zhao, John Scholler, Carl H. June
  • Patent number: 10788493
    Abstract: The present invention relates to a composition for diagnosing infectious diseases by using a tryptophanyl-tRNA synthase (WRS) and a method for detecting a diagnostic marker and, more specifically, to: a composition for diagnosing infectious diseases, containing a preparation measuring the WRS protein or mRNA expression level; a diagnostic kit; a method for detecting the WRS for providing information required for the diagnosis of infectious diseases, and a method for determining the infectious disease mortality risk by using the WRS. According to the present invention, the WRS is increased only in infection-induced infectious diseases, differentiating non-infectious diseases therefrom, and is rapidly increased in the early stage of infection. In addition, the level of the WRS is closely correlated with the severity and prognosis of diseases or complications induced by infection.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: September 29, 2020
    Assignee: JW BIOSCIENCE
    Inventors: Sunghoon Kim, Mi Rim Jin, Young Ha Ahn
  • Patent number: 10786576
    Abstract: The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3: wherein R1, R2, R3, R4, Ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as GDF15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease/steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: September 29, 2020
    Assignee: Novartis AG
    Inventors: Alexandra Marshall Bruce, Aaron Kanter, Changgang Lou, Aimee Richardson Usera, Jun Yuan, Frederic Zecri
  • Patent number: 10786535
    Abstract: Disclosed herein are methods of administering an agent targeting a lineage-specific cell-surface antigen and a population of hematopoietic cells that are deficient in the lineage-specific cell-surface antigen for immunotherapy of hematological malignancies.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: September 29, 2020
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Siddhartha Mukherjee, Florence Borot, Abdullah Mahmood Ali
  • Patent number: 10781238
    Abstract: Disclosed are a human-derived ferritin monomer fragment and a fusion polypeptide using the same, and more particularly, to a human-derived ferritin of which a portion of a fourth loop and a fifth helix of the ferritin monomer fragment are removed, and a fusion polypeptide in which a polypeptide or a protein is fused to an N-terminus or a C-terminus of the ferritin monomer fragment.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: September 22, 2020
    Assignees: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: So Youn Kim, Gwang-Seob Kim, Jun Young Seo, In-San Kim
  • Patent number: 10758611
    Abstract: Compositions and methods for co-expressing a secretable vaccine protein (such as gp96-Ig) and T-cell co-stimulatory molecules from a single vector, among others, are provided herein. Materials and methods for using gp96-Ig vaccination and T-cell co-stimulation to treat a clinical condition (e.g., cancer) in a subject also are provided.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: September 1, 2020
    Assignee: Heat Biologics, Inc.
    Inventors: Taylor Schreiber, George Fromm
  • Patent number: 10751370
    Abstract: The present invention relates to pharmaceutical compositions comprising mesenchymal cells (MSCs) and additional agents for blocking co-stimulation of the immune system. The compositions may optionally further comprise a therapeutic cell, a therapeutic tissue, and/or a therapeutic organ implant. Additionally, the instant invention pertains to medical uses of such compositions in immune-mediated diseases and disorders, in essentially all inflammatory and/or autoimmune diseases and conditions, and also in transplantation-related conditions.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: August 25, 2020
    Assignee: Swedish Stromabio AB
    Inventors: Matthias Corbascio, Makiko Kumagai
  • Patent number: 10745467
    Abstract: The present invention relates to a fusion proteins comprising regulatory T cell protein, VISTA (V-domain Immunoglobulin Suppressor of T cell Activation (PD-L3) and an immunoglobulin protein (Ig). The invention also provides the use of VISTA polypeptides, multimeric VISTA polypeptides, VISTA-conjugates (e.g., VISTA-Ig), and VISTA antagonists for the treatment of autoimmune disease, allergy, and inflammatory conditions.
    Type: Grant
    Filed: June 24, 2013
    Date of Patent: August 18, 2020
    Assignees: THE TRUSTEES OF DARTMOUTH COLLEGE, KING'S COLLEGE LONDON
    Inventors: Randolph J. Noelle, Sabrina Ceeraz, Isabelle LeMercier, Elizabeth Nowak, Janet Lines
  • Patent number: 10730929
    Abstract: This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a WAP domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: August 4, 2020
    Assignee: Inhibrx LP
    Inventors: Brendan P. Eckelman, John C. Timmer, Peter L. Nguy, Grant B. Guenther, Quinn Deveraux
  • Patent number: 10702593
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: July 7, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Oliver Schoor, Andrea Mahr, Toni Weinschenk, Anita Wiebe, Jens Fritsche, Harpreet Singh
  • Patent number: 10702592
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: July 7, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Oliver Schoor, Andrea Mahr, Toni Weinschenk, Anita Wiebe, Jens Fritsche, Harpreet Singh
  • Patent number: 10695438
    Abstract: The present invention relates to modified citrullinated enolase peptides that can be used as targets for cancer immunotherapy. These peptides can be used as vaccines or as targets for monoclonal antibody (mAb) therapy. Such vaccines or mAbs may be used in the treatment of cancer.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: June 30, 2020
    Assignee: Scancell Limited
    Inventors: Linda Gillian Durrant, Victoria Anne Brentville, Rachel Louise Metheringham
  • Patent number: 10690661
    Abstract: Provided herein are compositions and systems comprising yeast-based biosensors (YBBs) and methods of use thereof. In particular, YBBs are provided for the detection and/or quantification of an analyte (e.g., peptide analyte) in a sample (e.g., a biological sample, environmental sample, etc.). In some embodiments, provided herein are diagnostic compositions, devices, and methods comprising yeast-based biosensors (YBBs) engineered to detect analytes (e.g., peptides (e.g., biomarker peptides, etc.), etc.). In some embodiments, YBBs comprise (a) recognition element (e.g., receptor (e.g., modified yeast receptor, etc.), etc.) on the exterior of the biosensor (e.g., for binding and or recognition of the analyte (e.g., peptide)), and (b) a reporter that signals binding or recognition of the analyte. In some embodiments, a recognition element is a cell surface receptor.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: June 23, 2020
    Assignee: Northwestern University
    Inventors: Keith E. J. Tyo, Adebola V. Adeniran, John W. Bostick, Dante A. Pertusi, Sarah Christine Stainbrook
  • Patent number: 10676748
    Abstract: Consumer product compositions comprise a surfactant and a nucleic acid aptamer. The nucleic acid aptamer comprises at least one oligonucleotide comprising: deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, or mixtures thereof. The nucleic acid aptamer has a binding affinity for an epitope of a surface being treated with the consumer product composition.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: June 9, 2020
    Assignee: The Procter & Gamble Company
    Inventors: Juan Esteban Velasquez, Amy Violet Trejo, Paul Albert Sagel, Gregory Allen Penner
  • Patent number: 10668103
    Abstract: Disclosed herein are methods of administering an agent targeting a lineage-specific cell-surface antigen and a population of hematopoietic cells that are deficient in the lineage-specific cell-surface antigen for immunotherapy of hematological malignancies.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: June 2, 2020
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Siddhartha Mukherjee, Florence Borot, Abdullah Mahmood Ali
  • Patent number: 10660919
    Abstract: Disclosed herein are methods of administering an agent targeting a lineage-specific cell-surface antigen and a population of hematopoietic cells that are deficient in the lineage-specific cell-surface antigen for immunotherapy of hematological malignancies.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: May 26, 2020
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Siddhartha Mukherjee, Florence Borot, Abdullah Mahmood Ali
  • Patent number: 10654911
    Abstract: The present invention relates to a co-expression vector that comprises both truncated von Williebrand Factor (vWF)-Fc DNA construct and B-domain deleted FVIII DNA construct in the same vector. By co-expressing FVIII and truncated vWF-Fc with one expression vector in cells, the present invention controls the ratio of gene templates for FVIII and vWF proteins, provides a higher protein ratio of FVIII to vWF during cell expression, that results in a better occupancy of FVIII in vWF, and creates a higher yield (>1000 IU/ml) and more stable expression of FVIII protein molecules. In one preferred embodiment, the truncated vWF contains mutations of cysteines in the D?D3 domain of vWF to reduce multimer assembly of recombinant vWF during expression, and thus increasing recovery and quality of FVIII.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: May 19, 2020
    Assignee: Beijing Neoletix Biological Technology Co., Ltd.
    Inventors: Qi Li, Hailong Zhang
  • Patent number: 10646587
    Abstract: Recombinant adenoviral vectors, immunogenic compositions thereof and their use in medicine, and methods for generating recombinant adenoviral vectors are provided. In particular, the an adenovirus vector having a capsid derived from chimpanzee adenovirus AdY25, wherein the capsid encapsidates a nucleic acid molecule comprising an exogeneous nucleotide sequence of interest are provided.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: May 12, 2020
    Assignee: OXFORD UNIVERSITY INNOVATION LIMITED
    Inventors: Matthew Douglas James Dicks, Matthew Guy Cottingham, Adrian Vivian Sinton Hill, Sarah Gilbert
  • Patent number: 10640553
    Abstract: The present invention provides compositions and methods for regulating the specificity and activity of T cells. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “KIR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: May 5, 2020
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Michael Milone, Enxiu Wang
  • Patent number: 10633449
    Abstract: The invention relates to methods of treating fibrosis and inflammatory bowel disease. In one embodiment, the present invention treats gut inflammation by administering a therapeutically effective dosage of TL1A inhibitors and/or DR3 inhibitors to an individual. In another embodiment, the present invention provides a method of reversing tissue fibrosis in an individual by inhibiting TL1A-DR3 signaling function.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: April 28, 2020
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventors: David Q. Shih, Stephan R. Targan, Dalin Li, Janine Bilsborough
  • Patent number: 10632152
    Abstract: The present disclosure provides a heterodimeric, conditionally active chimeric antigen receptor (CAR), and a nucleic acid comprising a nucleotide sequence encoding the CAR. The present disclosure provides cells genetically modified to produce the CAR. A CAR of the present disclosure can be used in various methods, which are also provided.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: April 28, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Chia-Yung Wu, James Onuffer, Wendell A. Lim
  • Patent number: 10619155
    Abstract: The invention relates to methods and kits for labeling and manipulating a cellular circuit. The methods includes transfecting a first-order cell in the cellular circuit with a nucleic acid molecule encoding a tethered ligand, and a second-order cell in the cellular circuit with a nucleic acid molecule encoding a receptor and an effector fusion polypeptide, a nucleic acid molecule encoding a receptor interactor and protease fusion polypeptide, and a nucleic acid molecule encoding a reporter/modifier gene.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: April 14, 2020
    Assignee: BROWN UNIVERSITY
    Inventors: Gilad Barnea, Mustafa Talay, Ethan Richman, John Szymanski, Mark Johnson, John Fisher, Nathaniel Snell
  • Patent number: 10613092
    Abstract: Aspects of the present disclosure provide methods for determining the eligibility of a subject having a malignancy for treatment with an anti-PD therapeutic agent based on a Combined Positive Score (CPS) for a tumor tissue sample from the subject. Compositions and kits or performing the disclosed methods are also provided.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: April 7, 2020
    Assignees: Agilent Technologies, Inc., Merck Sharp & Dohme Corp.
    Inventors: Karina Kulangara, Nancy Zhang, David Stanforth, Greg Angelides, Stephanie Waldroup, Kenneth Emancipator
  • Patent number: 10605810
    Abstract: The present invention relates to a pincer for binding to a target material, wherein an antibody or a fragment thereof binding to a first target site of the target material and an aptamer binding to a second target site are conjugated via a linker, a preparation method thereof, a composition for detecting or separating the target material comprising the pincer, a kit for detecting or separating the target material comprising the composition, and a method for detecting or separating the target material using the kit. Also, the present invention relates to a drug carrier comprising the pincer for binding to a target material, wherein an aptamer conjugated to a second target site of the pincer loads the drug.
    Type: Grant
    Filed: December 26, 2014
    Date of Patent: March 31, 2020
    Assignee: University-Industry Cooperation Group of Kyung Hee University
    Inventors: Sang Soo Hah, Sung Muk Kang
  • Patent number: 10603380
    Abstract: The invention provides a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising extracellular domain disclosed herein. Some aspects of the invention relate to a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising the extracellular domain disclosed herein. Other aspects of the invention relate to cells comprising the CAR or the TCR and their use in a T cell therapy.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: March 31, 2020
    Assignee: KITE PHARMA, INC.
    Inventor: Jed Wiltzius
  • Patent number: 10591485
    Abstract: There are provided dicysteine peptide tags for use with dimaleimide fluorescent labelling agents for the labelling and detection of specific protein targets. Peptide tags comprising the amino acid sequence set forth in SEQ ID NO: 2 are described.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: March 17, 2020
    Assignee: UNIVERSITY OF OTTAWA
    Inventors: Jeffrey Keillor, Miroslava Strmiskova
  • Patent number: 10577424
    Abstract: An isolated monoclonal antibody or the antigen binding portion thereof that specifically binds human VISTA. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody or the antigen binding portion thereof are also provided. The present disclosure further provides a bispecific molecule, and a pharmaceutical composition comprising the antibody or the binding moieties thereof, as well as a treatment method using an anti-VISTA antibody or the antigen binding portion thereof of the present disclosure.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: March 3, 2020
    Assignee: Beijing Mabworks Biotech Co., Ltd.
    Inventors: Wenqi Hu, Jiangmei Li, Feng Li
  • Patent number: 10576128
    Abstract: The present invention relates to liquid pharmaceutical compositions of a VEGF antagonist for intravitreal administration comprising a histidine buffer, an inorganic salt, a carbohydrate and a polysorbate.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: March 3, 2020
    Assignee: FORMYCON AG
    Inventor: Rainer Sigl
  • Patent number: 10568932
    Abstract: The present invention relates to methods of treating Asthma using Semaphorin 3A. The invention further relates to assessing Asthma severity or treatment efficacy, comprising determining Semaphorin 3A level in a biological sample of a subject afflicted with Asthma.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: February 25, 2020
    Assignee: MEDICAL RESEARCH & DEVELOPMENT FUND FOR HEALTH SERVICES BNAI ZION MEDICAL CENTER
    Inventors: Zahava Vadasz, Elias Toubi
  • Patent number: 10568910
    Abstract: The invention includes compositions and methods related to multimodal therapies, e.g., for treating a cancer. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cancer.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: February 25, 2020
    Assignee: RUBIUS THERAPEUTICS, INC.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Robert J. Deans, Tiffany F. Chen, John Round, Noubar B. Afeyan, Torben Straight Nissen, Nathan Dowden, Tom Wickham, Sivan Elloul
  • Patent number: 10562954
    Abstract: The present invention provides a fusion protein inhibiting TACI-BAFF complex formation and preparation method therefor and use thereof. Specifically, the fusion protein of the present invention is of high biological activity for blocking BAFF/APPRIL, and may significantly lower the serum IgM concentration in normal Balb/c mice as well as the serum IgM and IgE concentration in C57/B6 mice with asthma. The TACI-Fc fusion protein of the present invention may be used in the treatment of autoimmune diseases, including asthma, systemic lupus eythematosus and rheumatoid arthritis, etc., and may also be used in the treatment of B cell enrichment-related diseases, including multiple myeloma, chronic lymphocytic leukemia, macroglobulinemia and plasmacytic leukemia, etc.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: February 18, 2020
    Assignees: Shanghai Kanda Biotechnology Co., Ltd., Shanghai Celgen Bio-Pharmaceutical Co., Ltd.
    Inventors: Zeling Cai, Yi Chen, Heng Wu, Guobo Fang
  • Patent number: 10568158
    Abstract: In one set of embodiments, one or more client stations operate to configure Neighbor Awareness Networking (NAN)—direct communication with neighboring client stations, i.e., direct communication between the client stations without utilizing an intermediate access point. Embodiments of the disclosure relate to NAN datapath scheduling and NAN pre-datapath operation setup and scheduling. The NAN datapath embodiments described herein provide a mechanism through which devices can communicate and provide services. Aspects of the datapath development include datapath scheduling, including datapath setup and scheduling attributes, as well as pre-datapath operation triggering and scheduling. Scheduling may include determination of a type of datapath, including paging and synchronized datapaths. NAN data cluster base schedules may be scheduled as equal-sets or subsets of datapath schedules. The datapath model may be implemented for unicast and multicast communication between client stations.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: February 18, 2020
    Assignee: Apple Inc.
    Inventors: Yong Liu, Christiaan A. Hartman, Daniel R. Borges, Peter N. Heerboth, Lawrie Kurian, Su Khiong Yong, Anand Rajagopalan, Saravanan Balasubramaniyan, Tashbeeb Haque, Andreas Wolf, Guoqing Li, Lilach Zukerman, Oren Shani
  • Patent number: 10550126
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-?]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: February 4, 2020
    Assignee: AbbVie Inc.
    Inventors: Aileen L. Pangan, Henrique D. Teixeira, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder
  • Patent number: 10550432
    Abstract: The present invention relates to a method of predicting the risk of developing ankylosing spondylitis using DNA copy number variation. It was verified that the risk of developing ankylosing spondylitis can be effectively predicted using primers for detecting DNA copy number variation, of the present invention, and the sensitivity and specificity of prediction can be improved by grafting the results of single nucleotide polymorphism (SNP) measurements, and thus more fundamental approaches for preventing and treating ankylosing spondylitis are expected.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: February 4, 2020
    Assignee: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION
    Inventors: Yeun-Jun Chung, Tae-Hwan Kim, Seung Cheol Shim, Seung-Hyun Jung
  • Patent number: 10519240
    Abstract: The present invention provides agonists of FGF21 signaling. In particular, the present invention provides FGF21 receptor (FGF21R) agonists that are capable of simultaneously binding ?Klotho (KLB) and/or FGFR1c to mimic the signaling activity of FGF21. The present invention also provides anti-FGF21 and anti-KLB/FGFR1c antibodies and antigen-binding fragments thereof. Also provided are methods of treating various metabolic disorders by administering the FGF21R agonists and/or anti-FGF21 antibodies to a subject in need thereof.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: December 31, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: George D. Yancopoulos, Andrew J. Murphy, Jesper Gromada, David R. Buckler, Kihwa Kang
  • Patent number: 10507234
    Abstract: The present invention relates to methods and pharmaceutical compositions of inducing immune tolerance by mucosal vaccination with Fc-coupled antigens. In particular, the present invention relates to a method for inducing tolerance to one antigen of interest in a subject in need thereof, comprising the mucosal administration to the subject of a therapeutically effective amount of a recombinant chimeric construct comprising a FcRn targeting moiety and an antigen-containing moiety.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: December 17, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DESCARTES, UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6), UNIVERSITE PARIS DIDEROT—PARIS 7
    Inventors: Roberto Mallone, Slobodan Culina, Nimesh Gupta, Sebastien Lacroix-Desmazes
  • Patent number: 10508143
    Abstract: Compositions, e.g., compositions comprising cellular therapeutics and/or protein therapeutics, and methods of using such compositions for treating cancer are described.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: December 17, 2019
    Assignee: Aleta Biotherapeutics Inc.
    Inventors: Roy Lobb, Paul Rennert
  • Patent number: 10501775
    Abstract: Isolated antigen binding molecules that specifically binds to a molecule comprising an amino acid sequence selected from the group consisting of GSTSGSGKPGSGEGSTKG (SEQ ID NO: 1), GSGKPGSGEG (SEQ ID NO: 2), GKPGSGEG (SEQ ID NO: 3), SGKPGSGE (SEQ ID NO: 499) and KPGSG (SEQ ID NO: 500) are provided. The antigen binding molecules can be used in the methods provided herein.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: December 10, 2019
    Assignee: Kite Pharma, Inc.
    Inventors: Jed Wiltzius, Stuart Sievers, Arianne Perez Garcia
  • Patent number: 10493136
    Abstract: An immunity-inducing agent comprising as an effective ingredient a specific polypeptide is disclosed. These polypeptides were isolated, by the SEREX method using a cDNA library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing specifically in serum derived from a cancer-bearing living body. The polypeptides can induce immunity in a living body and cause regression of a tumor in a cancer-bearing living body. Therefore, these polypeptides are especially effective as a therapeutic and/or prophylactic agent for a cancer(s).
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: December 3, 2019
    Assignee: TORAY INDUSTRIES, INC.
    Inventors: Masaki Ishibashi, Fumiyoshi Okano
  • Patent number: 10471103
    Abstract: Methods of treatment are provided herein, including administration of a population cells modified to enforce expression of an E-selectin and/or an L-selectin ligand, the modified cell population having a cell viability of at least 70% after a treatment to enforce such expression.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: November 12, 2019
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventor: Robert Sackstein
  • Patent number: 10474681
    Abstract: In an example, a method includes generating a targeted communication to respective computing devices of one or more members of an online social networking service, electronically collecting the responses to the targeted communication, mapping the responses to a cohort by updating a record in a database of members, the record identifying the cohort for the respective member, filtering information corresponding to a cohort to provide filtered cohort, and suppressing displaying of information corresponding to the cohort in response to the filtered information for the cohort indicating one or more of the biases being above a bias threshold value.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: November 12, 2019
    Assignee: Microsoft Technology Licensing, LLC
    Inventors: Krishnaram Kenthapadi, Stuart MacDonald Ambler, Parul Jain
  • Patent number: 10464988
    Abstract: The present application provides antibody-TCR chimeric constructs comprising an antibody moiety that specifically binds to a target antigen fused to a TCRM capable of recruiting at least one TCR-associated signaling module. Also provided are methods of making and using these constructs.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: November 5, 2019
    Assignee: EUREKA THERAPEUTICS, INC.
    Inventors: Jingwei Lu, Zhiyuan Yang, Cheng Liu, Hong Liu, Yiyang Xu, Su Yan, Vivien Wai-Fan Chan, Lucas Horan
  • Patent number: 10456447
    Abstract: This invention provides methods of modulating immune responses in the skin. The invention further provides methods of treatment for psoriasis, epidermal and dermal inflammation, and associated dermal immunity conditions by administering to an individual patient in need an effective amount of Gal-7, functional fragments of Gal-7, or agonists of Gal-7.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: October 29, 2019
    Assignee: Consejo Nacional de Investigacions Cientificas y Técnicas
    Inventors: Gabriel A. Rabinovich, Juan Pablo Cerliani, Nicolás Alejandro Pinto
  • Patent number: 10449349
    Abstract: Single layer and multilayer vesicles with actives inside are delivered into living tissue. Then, the vesicles are disrupted using ultrasound. The vesicles are used to create an image in the tissue or for the delivery of certain actives to the skin.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: October 22, 2019
    Assignee: L'Oreal
    Inventors: James Christopher McInnes, John Streeter, Vincenzo Casasanta, III
  • Patent number: 10442852
    Abstract: Methods and compositions are provided for the treatment of a patient with intracranial hemorrhage (ICH). Methods include the use of the products of recombinant constructs such as those that contain lactoferrin, as well as fusion protein constructs of lactoferrin and Fc domain for IgG.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: October 15, 2019
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Marian L. Kruzel, Jaroslaw Aronowski
  • Patent number: 10442849
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: October 15, 2019
    Assignee: TCR2 THERABEUTICS INC.
    Inventors: Patrick Baeuerle, Gregory Sieczkiewicz, Robert Hofmeister
  • Patent number: 10435436
    Abstract: There is provided a composition for improving memory, learning ability, and cognitive ability. It has been confirmed that a peptide having a C-terminal region ended to GAG had an effect of improving the memory. In order for the peptide to have the effect, it has been confirmed that the peptide should be a peptide of which the length consists of at least 4 amino acids. Further, it has been confirmed that a peptide of which the length of the peptide having the C-terminal region ended to GAG consists of 5 to 9 amino acids has the same effect. As a result, the peptide of the present invention can be used as the composition for improving memory, learning ability, and cognitive ability.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: October 8, 2019
    Assignee: BRAINON INC.
    Inventor: Yong Koo Kang
  • Patent number: 10426819
    Abstract: The invention relates to methods for the temporal administration of EDA agonists, in particular EDI200, which correlate to optimal therapeutic response windows required for the formation of any EDA-dependent structures such as ectodermal appendages. Use of the methods described allow for the design of targeted therapeutic dosing and administration regimens in order to correct or alter abnormal phenotypes associated with genetic disorders, in particular, XLHED.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: October 1, 2019
    Assignee: ESPOIRXLHED SÀRL
    Inventors: Pascal Schneider, Christine Kowalczyk-Quintas